Long-term comparisons of the efficacy,safety,and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer

Abstract

Objective

To compare the efficacy, safety, and pregnancy outcomes of tamoxifen plus ovarian function suppression (OFS) between Han and Zhuang women with hormone receptor-positive breast cancer.

Methods

A total of 236 Han and 101 Zhuang women with hormone receptor-positive breast cancer who received tamoxifen plus OFS were analyzed retrospectively. Long-term disease-free survival (DFS) and overall survival (OS) were evaluated by Kaplan–Meier analysis, and adverse events and pregnancy outcomes were assessed by χ² and Fisher’s exact-probability tests.

Results

There was no significant difference in DFS or OS between Han and Zhuang women (5-year DFS 74.57% and 77.23%, OS 85.59% and 90.01%, respectively). The incidences of endometrial hyperplasia, ovarian cysts, nausea and vomiting, fatty liver, retinitis, and thrombocytopenic purpura were similar in both groups, but Zhuang women had significantly more allergic reactions (6.93% vs. 2.12%). Pregnancy rates among women who attempted pregnancy were similar (Han, 7/138, 5.07%; Zhuang, 2/46, 4.35%).

Conclusions

OFS plus tamoxifen resulted in similar DFS and OS among premenopausal Han and Zhuang women with hormone receptor-positive breast cancer. However, Zhuang women were more likely to experience an allergic reaction. For women with fertility concerns, OFS plus tamoxifen was associated with similar pregnancy rates in Zhuang and Han women.

Keywords

Efficacy adverse event pregnancy breast cancer tamoxifen ovarian function suppression

Introduction

Recent studies have shown that breast cancer is the most common malignancy in women and is associated with poor survival, particularly among premenopausal women.¹ It is therefore important to investigate novel and effective therapeutic treatments for breast cancer.² Comprehensive therapy currently consists of surgery, chemotherapy, radiotherapy, and hormone therapy as mainstream modalities.³ Although adjuvant oral tamoxifen is one of the most effective hormone therapies in hormone receptor-positive premenopausal breast cancer patients,⁴ fertility concerns remain an important factor affecting treatment strategies in young breast cancer patients.⁵

The American Society of Clinical Oncology (ASCO) 2014 guidelines suggested that tamoxifen alone should be used for an initial 5-year period in premenopausal patients with hormone receptor-positive breast cancer,⁶ and a meta-analysis of the Early Breast Cancer Trialists’ Collaborative Group demonstrated that 5 years of tamoxifen treatment was correlated with a significant reduction in breast cancer mortality.⁷

Loss of ovarian function and fertility constitute severe side effects of breast cancer treatment protocols, particularly chemotherapy.⁵ Ovarian function suppression (OFS) has been developed as a suitable strategy to protect ovarian function during chemotherapy, and accumulating evidence suggests that tamoxifen plus OFS results in better survival than tamoxifen alone.^8–10 In 2003, the International Breast Cancer Study Group initiated the SOFT trial to determine the value of adding OFS to tamoxifen, and the role of the aromatase inhibitor exemestane plus OFS in hormone receptor-positive premenopausal breast cancer patients, compared with tamoxifen alone.¹¹ The results of the SOFT trial suggested that the addition of OFS to tamoxifen was not beneficial in women with low-risk early-stage breast cancer, but did improve outcomes in women at higher risk of relapse who received adjuvant chemotherapy, but who had no treatment-induced amenorrhea.¹² Similar results were observed in the E-3193, INT-0142 trials.¹³

The SOFT trial is currently the largest study of its kind to investigate the effects of tamoxifen plus OFS, and its results have been accepted worldwide.¹⁴ However, the SOFT trial did not investigate correlations between tamoxifen or OFS plus tamoxifen and pregnancy outcomes in patients. According to ASCO and European Society for Medical Oncology guidelines, cryopreservation of oocytes or embryos is a suitable procedure for fertility preservation in cancer patients.^15,16 Lambertin¹⁷ and colleagues demonstrated that OFS exerted no effect on pregnancy in breast cancer patients; however, the effects of tamoxifen and OFS on pregnancy outcomes remain controversial.

Most recent large and authoritative clinical trials have enrolled few Chinese women, particularly from minority populations, and the efficacy, safety, and pregnancy outcomes following OFS plus tamoxifen in premenopausal Han Chinese women with hormone receptor-positive early breast cancer compared with women from minority Chinese populations are thus unknown. In addition, there are presently no research reports comparing these indices between Han and Zhuang populations in southern China. We therefore designed the present clinical study to explore such issues.

Patients and methods

Ethics statement

The study protocols were approved by the ethics committees of the Affiliated Cancer Hospital of Guangxi Medical University. All participants in this clinical research study were informed about the goals of the study before being enrolled, and written informed consent was obtained for the storage of patient information in our hospital database.

Patients

We retrospectively analyzed the medical records of patients diagnosed with breast cancer who were included in a prospective database of the Affiliated Cancer Hospital of Guangxi Medical University from January 2007 to December 2010. Study participants underwent either mastectomy, modified radical surgery, or breast-conserving surgery followed by radiotherapy. The use of chemotherapy was based on pathologic TNM stage and molecular subtype. Patients who received chemotherapy and remained premenopausal were also included within 8 months of completing chemotherapy, once estradiol (E2) concentrations had been assessed by a local laboratory.¹² The standard criteria for menopause were: age ≥60 years; having undergone bilateral ovariectomy; age <60 years, but with natural menopause for ≥12 months, follicle-stimulating hormone (FSH) and E2 levels in the menopausal range, and without chemotherapy, tamoxifen, or OFS; and age <60 years, but having undergone tamoxifen therapy, with FSH and E2 levels in the menopausal range. The same samples were subjected to repeat analysis in the laboratory to confirm the levels. Menopausal patients were then excluded.^4,6

Breast cancer patients who underwent their initial treatment at other centers, as well as patients who were postmenopausal, hormone receptor-negative, or who belonged to minorities other than Zhuang, and patients unwilling to receive tamoxifen treatment for personal reasons were also excluded.

Treatment and follow-up

All patients received an oral dose of 20 mg of tamoxifen daily. OFS was achieved voluntarily by either subcutaneous injection of leuprorelin 3.75 mg every 28 days or by bilateral oophorectomy.

After systemic treatment with surgery, chemotherapy, and/or radiotherapy, all patients underwent regular follow-up involving analysis of serum tumor marker levels, breast and abdominal ultrasonography, and chest radiography every 2–3 months for the first year after systemic treatment, every 6 months for the subsequent 5 years, and every 12 months thereafter. Investigation of breast tissue by magnetic resonance imaging and molybdenum target X-ray, evaluation of head, chest, and abdominal and pelvic cavities by computed tomography, isotopic bone scan, and curettage were carried out once a year.

All adverse events were recorded according to the results of follow-up. Pregnancy was evaluated during follow-up, and “no pregnancy” was defined as either pregnancy not desired or failed attempts. Patients who reported a term or preterm delivery, miscarriage, and/or induced abortion were considered as having undergone a pregnancy.¹⁷

Study endpoints

The primary endpoint was disease-free survival (DFS), defined as the time from enrollment to the first recurrence of invasive breast cancer (regional, local, or distant), the appearance of contralateral breast cancer, a second primary invasive cancer (non-breast), or death without recurrence. The secondary endpoint was overall survival (OS), defined as the time from enrollment to death from any cause or the end of follow-up.

Statistical analysis

We compared clinical and pathologic characteristics, treatment efficacy and safety, and pregnancy outcomes between Han and Zhuang women using χ² tests, or Fisher’s exact test if the value in a statistical cell was expected to be < 6. Differences between continuous data were analyzed by t-tests. Survival was analyzed by Kaplan–Meier analysis, and group results were compared using log-rank tests. All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA), and a P-value <0.05 was considered statistically significant.

Results

Study population

A total of 1475 southern Chinese women with early breast cancer were entered consecutively into the database during the study period. Among these, 357 (24.2%) women who underwent their initial breast cancer therapy at other centers, 443 (30.0%) with hormone receptor-negative breast cancer, 305 (20.7%) postmenopausal women, 27 (1.8%) women from minorities other than Han or Zhuang, and six (0.4%) patients who were unwilling to receive tamoxifen treatment for personal reasons were excluded. The remaining 337 patients (22.8%) were then included in the present study (Figure 1).

Figure 1.

Selection of study patients.

Among the final cohort of 337 women, 236 were ethnic Han and 101 were ethnic Zhuang. All received oral tamoxifen 20 mg daily and a subcutaneous injection of leuprorelin 3.75 mg every 28 days (Figure 1).

Clinicopathologic data

The clinicopathologic and demographic data of the 337 enrolled patients are summarized in Table 1. Most clinicopathologic features were similar in both population groups at baseline (Table 1), with no significant difference in age, tumor invasion depth, number of metastatic lymph nodes, estrogen receptor status, progesterone receptor status, HER-2 status, or pathological type (Table 1).

Table 1.

Comparison of clinicopathological characteristics between Han and Zhuang women with hormone receptor-positive breast cancer.

Variable	Total(n = 337)	Han(n = 236)	Zhuang(n = 101)	χ²	P-value
Age (years)					0.179
Median (range)		41 (26–50)	44 (31–52)
Tumor invasion depth				0.020	0.990
≤2 cm	72	50	22
>2 cm, ≤5 cm	241	169	72
>5 cm	24	17	7
No. of lymph nodes				1.309	0.520
0	16	10	6
1–3	185	134	51
≥4	136	92	44
ER status				0.958	0.328
Negative	29	18	11
Positive	308	218	90
PR status				0.125	0.724
Negative	26	19	7
Positive	311	217	94
HER-2 status				0.763	0.383
Negative	267	184	83
Positive	70	52	18
Pathological type				4.578	0.101
Invasive ductal carcinoma	185	138	47
Invasive lobular carcinoma	90	60	30
Other	62	38	24

HER-2 positive indicates positive for HER-2 by fluorescence in situ hybridization or chromogenic in situ hybridization test or (+++) in immunohistochemistry test according to National Comprehensive Cancer Network guidelines 2011. Positivity for ER and PR defined according to American Society of Clinical Oncology and College of American Pathologists 2010 guidelines, which recommended positivity criteria for ER and PR as ≥1% of positive nuclear staining.

HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor; ER, estrogen receptor.

Efficacy and survival

DFS was compared between the two groups using Kaplan–Meier analysis and the log-rank test. There was no significant difference between the ethnic groups in terms of DFS (Figure 2). Among the 83 DFS events analyzed, Han women accounted for 60 events and Zhuang women for 23. The estimated 5-year DFS rates were 74.57% (95% confidence interval [CI], 65.87–86.23%) for Han versus 77.23% (95% CI, 67.08–89.46%) for Zhuang women. Neither population attained the median DFS.

Figure 2.

Comparison of disease-free survival between Han (n=236) and Zhuang women (n=101) with hormone receptor-positive breast cancer treated with oral tamoxifen 20 mg daily and ovarian function suppression with subcutaneous injection of leuprorelin 3.75 mg every 28 days.

Similar to DFS, there was no significant difference between the groups in terms of OS, as demonstrated by Kaplan–Meier analysis and log-rank test (Figure 3). In the final analysis, 34 (14.4%) deaths were observed in the Han population versus 10 (9.90%) in the Zhuang population. The median OS for Han women was 113.63 months, but the median was not reached in the Zhuang population. The 5-year estimated OS rates for the Han and Zhuang populations were 85.59% (95% CI, 80.03–91.26%) and 90.01% (95% CI, 85.87–94.51%), respectively.

Figure 3.

Comparison of overall survival between Han (n=236) and Zhuang women (n=101) with hormone receptor-positive breast cancer treated with oral tamoxifen 20 mg daily and ovarian function suppression with subcutaneous injection of leuprorelin 3.75 mg every 28 days.

Safety

We investigated the safety profiles and adverse events in the two populations. The most common grade 3 or 4 adverse events were endometrial hyperplasia (simple hyperplasia and atypical hyperplasia),^18–20 ovarian cysts,²¹ nausea and vomiting,²² fatty liver,²³ retinitis,^24,25 thrombocytopenic purpura,²⁶ and allergy,²⁷ as reported previously. We found no significant differences between the Han and Zhuang populations in terms of non-endometrial hyperplasia (31.78% vs. 32.67%), ovarian cysts (17.38% vs. 13.86%), nausea and vomiting (3.39% vs. 1.98%), fatty liver (16.95% vs. 17.82%), retinitis (6.36% vs. 3.96%), or thrombocytopenic purpura (6.36% vs. 8.91%) (Table 2). However, the Zhuang population exhibited a significantly higher rate of allergic events (6.93%) compared with the Han population (2.12%) (P = 0.048) (Table 2).

Table 2.

Occurrence of grade 3 or 4 adverse events in Han and Zhuang women with hormone receptor-positive breast cancer treated with tamoxifen plus ovarian function suppression.

Adverse event, n (%)	Total(n = 337)	Han(n = 236)	Zhuang(n = 101)	χ²	P-value	HR	95% CI
Endometrial hyperplasia				0.026	0.872	0.960	0.583–1.579
Yes	108 (32.05)	75 (31.78)	33 (32.67)
No	229 (67.95)	161 (66.82)	68 (67.33)
Ovarian cyst				0.639	0.424	1.307	0.677–2.521
Yes	55 (16.32)	41 (17.38)	14 (13.86)
No	282 (83.68)	195 (82.62)	87 (86.14)
Nausea and vomiting				0.488	0.729	1.737	0.362–8.326
Yes	10 (2.97)	8 (3.39)	2 (1.98)
No	327 (97.03)	228 (96.61)	99 (98.02)
Fatty liver				0.038	0.846	0.941	0.510–1.737
Yes	58 (17.21)	40 (16.95)	18 (17.82)
No	279 (82.79)	196 (83.05)	83 (82.18)
Retinitis				0.763	0.451	0.549	0.144–2.088
Yes	19 (5.64)	15 (6.36)	4 (3.96)
No	318 (94.36)	221 (93.64)	97 (96.04)
Thrombocytopenic purpura				0.698	0.403	1.646	0.532–5.088
Yes	23 (6.82)	15 (6.36)	9 (8.91)
No	313 (93.18)	221 (93.64)	92 (91.09)
Allergy				4.769	0.048	0.291	0.090–0.939
Yes	12 (3.56)	5 (2.12)	7 (6.93)
No	325 (96.44)	231 (97.88)	94 (93.07)

HR, hazard ratio; CI, confidence interval.

Pregnancy

We also investigated the incidences of pregnancy in both ethnic groups, excluding 98 (41.52%) Han and 55 Zhuang women (54.46%) who did not attempt pregnancy. Among the remaining participants, the pregnancy rates were similar in the two groups, with seven pregnancies (5.07%) among 138 Han women and two (4.35%) among 46 Zhuang women (Table 3). No congenital abnormalities or preterm deliveries occurred among the nine offspring.

Table 3.

Pregnancy rates in Han and Zhuang women with hormone receptor-positive breast cancer treated with tamoxifen plus ovarian function suppression.

Pregnancy occurrence, n (%)	Total(n = 184)	Han(n = 138)	Zhuang(n = 46)	χ²	P-value	HR	95% CI
Pregnancy	9 (4.89)	7 (5.07)	2 (4.35)	0.039	>0.95	0.851	0.170–4.248
No pregnancy	175 (95.11%)	131 (94.93)	44 (95.65)	0.039	>0.95	0.851	0.170–4.248

HR, hazard ratio; CI, confidence interval.

Discussion

China’s population includes 56 ethnic groups, with Han individuals constituting 96% of the population and the autonomous region of Guangxi Province in southern China having the largest Zhuang population. Increasing evidence has shown oncogenic variations among different minorities in China that may be associated with differences in cancer morbidities;²⁸ however, there has been scant research comparing health outcomes among different populations undergoing the same treatment modalities. We therefore compared health issues between different ethnic groups, on the basis of the identity cards presented by the patients at their first hospital attendance.

To the best of our knowledge, the present study represents one of the largest studies to investigate the efficacy and safety of adjuvant tamoxifen plus OFS in Han and Zhuang women with hormone receptor-positive breast cancer living in southern China. The results demonstrated that DFS and OS rates were similar in women from both ethnic groups following treatment with tamoxifen and OFS. The rates of adverse events were also similar, except for allergic reactions, which were more common among Zhuang women. Furthermore, the current results provide the first evidence indicating similar pregnancy rates in the two groups after treatment.

For more than two decades, endocrine therapy for breast cancer has included tamoxifen, letrozole, anastrozole, and exemestane, all of which have made significant contributions to breast cancer therapy.^29–31 Large clinical trials have focused on investigating and comparing the efficacies of each endocrine drug. SOFT and TEXT clinical trials demonstrated that exemestane plus OFS and tamoxifen plus OFS exhibited better outcomes than tamoxifen alone in breast cancer patients with a high composite risk.^32,33 The ABCSG-12 clinical trial compared tamoxifen plus goserelin with anastrozole plus goserelin for > 3 years and showed that, although OS was higher with tamoxifen compared with anastrozole, there was no significant difference in DFS between the two treatment arms.³⁴ Most large clinical trials have not considered the effects of ethnicities or minority participants. However, we accordingly compared the treatment effects of OFS plus tamoxifen in Han and Zhuang cohorts in southern China. The 5-year DFS survival rates were similar in both ethnic groups (74.57% in Han and 77.23% in Zhuang), indicating that OFS plus tamoxifen provided similar therapeutic efficacies with respect to preventing recurrence in both populations. A similar phenomenon was observed for OS (85.59% in Han and 90.01% in Zhuang). Guangxi is a Zhuang autonomous region in southern China and home to millions of Zhuang residents.³⁵ The results of the current study indicated similar long-term outcomes in Han and Zhuang patients with hormone receptor-positive breast cancer treated with OFS plus tamoxifen, suggesting that Zhuan ethnicity is not a critical factor influencing survival, and the same endocrine strategies (OFS plus tamoxifen) can therefore be used in both Han and Zhuang populations. Given that recent research efforts have focused on oncogene expression or clinical characteristics in different minorities rather than on differences in outcomes of the same treatment strategy,^36,37 the current study represents a novel area of investigation.

Tamoxifen therapy is associated with adverse events including endometrial hyperplasia (simple or atypical hyperplasia), ovarian cysts, nausea and vomiting, fatty liver, retinitis, thrombocytopenic purpura, and allergy. Although previous large clinical trials have reported adverse event rates,³⁸ data regarding differences in these rates between/among different races and minorities are lacking. We detected similar adverse events to previous studies,³⁸ and found no difference between Han and Zhuang women in terms of endometrial hyperplasia, ovarian cysts, nausea and vomiting, fatty liver, retinitis, or thrombocytopenic purpura. In contrast, however, Zhuang women exhibited a significantly higher rate of allergic reactions than Han women (6.93% vs. 2.12%), suggesting that the Zhuang population was hypersensitive to tamoxifen plus OFS. On the basis of these results, routine treatments for adverse events are suitable for both Han and Zhuang women, but additional anti-allergen treatment may be beneficial in Zhuang patients. The current results were analyzed using small-sample statistics, and further studies with larger sample sizes are needed to confirm our conclusions.

Breast cancer therapy (especially chemotherapy) is associated with significant side effects in premenopausal women, including the possible loss of ovarian function and fertility.^5,14,39 Although fertility and pregnancy are thus of intense importance to young women with breast cancer, considerable controversy remains regarding how fertility and pregnancy concerns affect fertility preservation or treatment decision strategies at the time of the initial cancer diagnosis. Kathryn⁵ and colleagues focused on fertility concerns and breast cancer treatment and suggested that many young women with newly diagnosed breast cancer had concerns about fertility, which could substantially affect their treatment decisions. However, despite their comprehensive research studies regarding fertility concerns and breast cancer treatment, the authors could not demonstrate how the choice of treatment regimens might influence pregnancy rates or ascertain which type of treatment decision strategies were suitable for breast cancer patients concerned about fertility. Lambertini et al.¹⁷ investigated the correlations among chemotherapy, OFS, and pregnancy and showed that treatment regimens comprising chemotherapy plus OFS had no effect on pregnancies in women with breast cancer compared with chemotherapy alone. Despite these clinical studies, no previous studies have investigated differences in the effects of OFS plus tamoxifen on pregnancy rates between minority races or ethnicities. The results of the current study revealed similar pregnancy rates of 5.07% and 4.35%, respectively, in Han and Zhuang women in southern China with hormone receptor-positive breast cancer following OFS plus tamoxifen therapy. This suggests that fertility preservation or treatment decision strategies at the time of initial breast cancer diagnosis may not need to take account of the patient’s ethnicity.

In conclusion, the current study showed that premenopausal Han and Zhuang women with hormone receptor-positive breast cancer experienced similar DFS and OS rates following OFS plus tamoxifen. The incidences of endometrial hyperplasia, ovarian cysts, nausea and vomiting, fatty liver, retinitis, and thrombocytopenic purpura were similar in both ethnic groups, but the incidence of allergic reactions was significantly higher among Zhuang compared with Han women. Notably, in relation to fertility concerns, OFS plus tamoxifen treatment was associated with similar pregnancy rates in Zhuang and Han women.

Footnotes

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81760481).

References

DeSantis

Fedewa

Goding

et al . Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66: 31–42.

Welch

Prorok

O'Malley

et al . Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 2016; 375: 1438–1447.

Greenlee

DuPont-Reyes

Balneaves

et al . Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67: 194–232.

Lambertini

Falcone

Unger

et al . Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer. J Clin Oncol 2017; 35: 804–805.

Ruddy

Gelber

Tamimi

et al . Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014; 32: 1151–1156.

Burstein

Temin

Anderson

et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2014; 32: 2255–2269.

Davies

Godwin

Gray

et al . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771–784.

Burstein

Lacchetti

Anderson

et al.

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression

. J Clin Oncol 2016; 34: 1689–1701.

Phillips

Regan

Ribi

et al . Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 2016; 114: 956–964.

10.

Jain

Santa-Maria

Gradishar

WJ.

The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer. Oncology (Williston Park) 2015; 29: 473–478, 481.

11.

Regan

Pagani

Fleming

et al . Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast 2013; 22: 1094–1100.

12.

Francis

Regan

Fleming

GF.

Adjuvant ovarian suppression in premenopausal breast cancer.

N Engl J Med 2015; 372: 1673.

13.

Tevaarwerk

Wang

Zhao

et al . Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32: 3948–3958.

14.

Lambertini

Del

Viglietti

et al . Ovarian function suppression in premenopausal women with early-stage breast cancer. Curr Treat Options Oncol 2017; 18: 4.

15.

Loren

Mangu

Beck

et al . Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500–2510.

16.

Peccatori

Azim

Orecchia

et al . Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi160–vi70.

17.

Lambertini

Boni

Michelotti

et al . Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 2015; 314: 2632–2640.

18.

Satyaswaroop

Zaino

Mortel

Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice.

Cancer Res 1984; 44: 4006–4010.

19.

Boccardo

Guarneri

Rubagotti

et al . Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984; 70: 61–68.

20.

Nomikos

Elemenoglou

Papatheophanis

Tamoxifen-induced endometrial polyp. A case report and review of the literature.

Eur J Gynaecol Oncol 1998; 19: 476–478.

21.

Mourits

de Vries

Willemse

et al . Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 1999; 79: 1761–1764.

22.

Rutqvist

Cedermark

Glas

et al . The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987; 10: 255–266.

23.

Cole

Jacobs

Vance

DE.

Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis.

Hepatology 2010; 52: 1258–1265.

24.

Kaiser-Kupfer

Lippman

ME.

Tamoxifen retinopathy.

Cancer Treat Rep 1978; 62: 315–320.

25.

Vinding

Nielsen

NV.

Retinopathy caused by treatment with tamoxifen in low dosage.

Acta Ophthalmol (Copenh) 1983; 61: 45–50.

26.

Enck

Rios

CN.

Tamoxifen treatment of metastatic breast cancer and antithrombin III levels.

Cancer 1984; 53: 2607–2609.

27.

Berstein

Wang

Zheng

et al . Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res 2004; 10: 1530–1534.

28.

Fan

Strasser-Weippl

et al . Breast cancer in China. Lancet Oncol 2014; 15: e279–289.

29.

Bourgier

Kerns

Gourgou

et al . Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. Ann Oncol 2016; 27: 474–480.

30.

Nerich

Saing

Gamper

et al . Cost-utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Res Treat 2016; 159: 407–424.

31.

Alba

Calvo

Albanell

et al . Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 2012; 23: 3069–3074.

32.

Regan

Francis

Pagani

et al . Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016; 34: 2221–2231.

33.

Pagani

Regan

Walley

et al . Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107–118.

34.

Gnant

Mlineritsch

Stoeger

et al . Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and Colorectal Cancer Study Group trial 12. Ann Oncol 2015; 26: 313–320.

35.

Fang

Zhou

et al . Paraoxonase 1 gene polymorphisms are associated with an increased risk of breast cancer in a population of Chinese women. Oncotarget 2017; 8: 25362–25371.

36.

Zhou

Zhuang

et al . Interleukin-10 -1082 promoter polymorphism and gastric cancer risk in a Chinese Han population. Mol Cell Biochem 2011; 347: 89–93.

37.

Zhou

Zhuang

et al . p53 Codon 72 polymorphism and gastric cancer risk in a Chinese Han population. Genet Test Mol Biomarkers 2010; 14: 829–833.

38.

Forbes

Sestak

Howell

et al . Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 2016; 387: 866–873.

39.

Partridge

Ruddy

Gelber

et al . Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010; 94: 638–644.